What's in Kwang-Ha Yoo's pipeline?

Kwang-Ha Yoo has 4 drugs in our index: 4 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Kwang-Ha Yoo's portfolio?

Top competitors by shared drug class: CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Sanofi, Shanghai Huilun Pharmaceutical Co., Ltd..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/kwang-ha-yoo.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Kwang-Ha Yoo — Portfolio Competitive Intelligence Brief

Kwang-Ha Yoo pipeline: 4 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

4 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Erdos capsule	Erdos capsule	marketed	norepinephrine reuptake inhibitor	norepinephrine transporter	Psychiatry
Placebo of Erdos capsule	Placebo of Erdos capsule	marketed
Bronpass Tab.	Bronpass Tab.	marketed
Placebo of Bronpass Tab.	Placebo of Bronpass Tab.	marketed

Therapeutic area mix

Psychiatry · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 1 shared drug class
Sanofi · 1 shared drug class
Shanghai Huilun Pharmaceutical Co., Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Kwang-Ha Yoo:

Cite this brief

Drug Landscape (2026). Kwang-Ha Yoo — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/kwang-ha-yoo. Accessed 2026-05-16.